Services on Demand
Journal
Article
Indicators
-
Cited by SciELO
-
Access statistics
Related links
-
Cited by Google
Similars in SciELO
-
Similars in Google
Share
International Journal of Morphology
On-line version ISSN 0717-9502
Int. J. Morphol. vol.25 no.3 Temuco Sept. 2007
http://dx.doi.org/10.4067/S0717-95022007000300019
Int. J. Morphol., 25(3):587-590, 2007.
PRP: A Possibility in Regenerative Therapy PRP: Una Posibilidad en Terapia Regenerativa
*Joao Paulo Mardegan Issa; *Rodrigo Tiossi; **Amaro Sergio da Silva Mello; ***Ruberval Armando Lopes; ***Miguel Angel Sala Di Matteo & ***Mamie Mizusaki Iyomasa * Graduate student, Faculty of Dentistry, University of Sao Paulo, Brazil. Dirección para correspondencia
SUMMARY: Arecent innovation in dentistry is the preparation and use of platelet-rich plasma (PRP), a concentrated suspension of the growth factors found in platelets. PRP is involved in wound healing and are postulated as promoters of tissue regeneration. This review represents an update of the uses, applications, mechanism of action and clinical benefits of PRP. KEY WORDS: PRP; Wound healing; Dentistry. RESUMEN: Innovaciones recientes en odontología son la preparación y uso de plasma enriquecido de plaquetas (platelet-rich plasma, PRP), una suspensión concentrada de factores de crecimiento presentes en las plaquetas. El PRP está involucrado en la cicatrización y se postula su acción como promotor de la regeneración tisular. Esta revisión corresponde a una actualización de los usos, aplicaciones, mecanismos de acción y beneficios clínicos del PRP. PALABRAS CLAVE: PRP; Cicatrización; Odontología.
INTRODUCTION Surgeons are continually searching for ways to improve the success of bone grafting with either autogenous bone or other bone substitutes. Platelet-rich plasma (PRP) was first introduced to the oral surgery community by Whitman et al. in their 1997 article entitled "Platelet Gel: An autologous alternative to fibrin glue with applications in oral and maxillofacial surgery". The authors thought that "through activation of the platelets within the gel and the resultant release of these growth factors, enhanced wound healing should be expected". PRP enjoyed a great increase in popularity in the oral and maxillofacial surgery community after the publication of a landmark article by Marx et al. in 1998. Marx study showed that combining PRP with autogenous bone in mandibular continuity defects resulted in significantly faster radiographic maturation and histomorphometrically denser bone regenerate. Platelet-rich plasma (PRP) is autologous concentration of human platelets in a small volume of plasma. Therefore, the term PRP is preferred to autologous platelet gel, plasma-rich growth factors (PRGFs), or a mere autologous platelet concentrate. Because it is a concentration of platelets, it is also a concentration of the 7 fundamental protein growth factors proved to be actively secreted by platelets to initiate all wound healing. These growth factors included the 3 isomeres of platelet-derived growth factor (PDGFaa, PDGFbb, and PDGFab), 2 of the numerous transforming growth factors-b (TGFbl andTGFb2), vascular endothelial growth factor, and epithelial growth factor. All of these growth factors have been documented to exist in platelets (Marx et al; Kevy & Jacobson, 2001). Because these concentrated platelets are suspended in a small volume of plasma, PRP is more that just a platelet concentrate; it also contains the 3 proteins in blood known to act as cell adhesion molecules for osteoconduction and as a matrix for bone, connective tissue, and epithelial migration. These cell adhesion molecules are fibrin itself, fibronectin, and vitronectin. The purpose of this article is to review the available literature about PRP and the impact of the growth factors it contains. The aim is to realize an update and to inform about the use, application, mechanism of action and clinical benefits of PRP. PRP CHARACTERISTICS The mechanism of PRP works. PRP works via the degranulation of the a granules in platelets, which contain the synthesized and prepackaged growth factors. The active secretion of these growth factors is initiated by the clotting process of blood and begins within 10 minutes after clotting. More than 95% of the presynthesized growth factors are secreted within 1 hour (Kevy & Jacobson). Therefore, PRP must be developed in an anticoagulated state and should be used on the graft, flap, or wound, within 10 minutes of clot initiation. Studies that have not used anticoagulated whole blood, which is then clotted to activate the PRP, are not really studies of PRP and therefore are misleading. Related to this, PRP has been shown to remain sterile and the concentrated platelets viable for up to 8 hours once developed in the anticoagulated state and placed on a sterile surgical table (Fig. 1A). How many platelets are enough? This question has been answered by the work of Haynesworth et al. (2002), who showed that the proliferation of adult mesenchymal stem cells and their differentiation were directly related to the platelet concentration. They showed a dose-response curve, which indicated that, a sufficient cellular response to platelet concentrations first began when a 4- to 5-fold increase over baseline platelet numbers was achieved. A similar study by Lui et al. (2002) showed that fibroblast proliferation and type I collagen production were also enhanced by increasing platelet concentrations and that much of the response was pH dependent with the best responses occurring at more acidic pH levels (Fig. IB). Effects of PRP Growth Factors on Cells Involved in Oral Wound Healing. The oral and maxillofacial wound healing involves gingival fibroblasts, gingival epithelial cells, periodontal ligament fibroblasts and osteoblasts, all of which are important for tissue repair and hard-tissue regeneration. A series of well-orchestrated cell-cell interactions is initiated after injury. Disruption of the vasculature as a result of injury leads to fibrin formation and platelet aggregation. Several growth factors are then released into the tissue from the platelets and from the adjacent cells after injury, including platelet-derived growth factor (PDGF), transforming growth factor-alpha, transforming growth factor-beta (TGF-b) andinsulin-like growth factor I (IGF-I) (Antoniades et al, 1993; Assoian etal., 1984; Sitaras etal., 1987); Weibrich et al, 2001). Bone and cementum may also release growth factors during wound healing (Giannobile, 1996). Periodontal and oral surgical techniques may involve use of these factors in both soft and mineralized tissues (Giannobile; Petrungaro, 2001; Schliephake, 2002). Clinical situations benefit from PRP. Because PRP enhances osteoprogenitor cells in the host bone and in bone grafts (Marx et al.; Weibrich et al, 2002), it has found clinical applications in fully autogenous bone grafts and composites of autogenous bone grafts with a variety of bone substitutes with as little as 20% autogenous bone (Garg, 2000). Therefore, PRP has shown improved results in continuity defects 2,15,16,17, sinus lift augmentation grafting (Kassolis et al, 2000; Lozada et al, 2001; Mendonca-Caridad et al, 2006), horizontal and vertical ridge augmentations (Garg), ridge preservation grafting (Carlson et al, 2002) and periodontal/peri-implant defects (Kim et al, 2002). We have also observed PRP to allow earlier implant loading and improved osseointegration when used in compromised bone such as osteoporotic bone and bone after radiotherapy. Because PRP also enhances soft tissue mucosal and skin healing, it is used in connective tissue grafts, palatal grafts, gingival grafts, mucosal flaps together with Alloderm (BioHorizons, Birmingham, AL) for root coverage, skin graft donor and recipient sites, dermal fat grafts, face lifts, blepharoplasty, and laser resurfacing surgery (Fig. 1C). Does PRP promote infections? Some have empirically suggested that PRP may promote infections due to the flawed logic that it is a blood clot and that blood agar is used in microbiology laboratories to culture bacteria. However, PRP is no different in substrate than the blood clot that forms in every wound and therefore could not support bacterial growth any more than any other blood clot (Marx, 2004). PRP-Recent studies. Human studies have also shown that PRP can be advantageously and easily applied in surgery. Man et al. (2001) used PRP in 20 patients undergoing cosmetic surgery, including face lifts, breast augmentations, breast reductions and neck lifts. The application of PRP yielded adequate hemostasis if platelet-poor plasma (PPP) was also applied to create a seal to halt bleeding. The authors reported that bleeding capillaries were effectively sealed within 3 minutes after application of the platelet gel (PRP) and fibrin glue (PPP). They also noted the advantage of minimizing use of electrocautery as to minimize the chance of damage to the adjacent nerves. They concluded that PRP offered significant benefits in terms of accelerated postoperative wound healing, tissue repair and regeneration if PPP was used as a hemostatic agent (Man et al). Hiramatsu et al. (2002) examined effects of reinfusion of autologous platelet concentrate after open heart surgery in patients with noncyanotic congenital heart disease. Reinfusion of freshly prepared autologous PRP was followed by good aggregation responses and low blood loss. The authors suggested that this procedure might be useful in pediatric open heart surgery to avoid blood transfusion and minimize the need for homologous blood products (Hiramatsu etal, 2002) (Fig. ID). CONCLUSION PRP is new application of tissue engineering and can be used in the most varied areas of the dentistry, being applied in periodontal and maxillofacial surgeries. It is a storage vehicle for growth factors, especially PDGF and TGF-6. Although growth factors and the mechanism involved are still poorly understood, the ease of applying PRP in the dental clinic and its beneficial outcomes hold promise for further procedures. However, that is new area of the science and many clinical results still will be published, especially in that refers to the efficiency of the procedures, application form, growth factors carriers, genetic modifications of the proteins and growth factors. Certainly, the use of PRP is a step in the history evolution of the regenerative methods and the tissue engineering that will be used next years.
REFERENCES Antoniades, H. N.; Galanopoulos, T.; Neville-Golden, J.; Kiritsy, C. P. & Lynch, S. E. Expression of growth factor and receptor mRNA in skin epithelial cells following acute cutaneous injury. Am. J. Pathol, 142:1099-110, 1993. Assoian, R. K.; Grotendorst, G. R.; Muller, D. M. & Sporn, M.B. Cellular transformation by coordinated action of three peptide growth factors from human platelets. Nature, 509:804-16, 1984. Carlson, N.E.; Roach, R.B.Jr. Platelet rich plasma: Clinical applications in dentistry. J. Am. Dent. Assoc, 133: 1383-6, 2002. Garg, A. K. The use of platelet rich plasma to enhance the success of bone grafts around dental implants. Dent. Implantol. Update., 11:17-21,2000. Giannobile, W. V. Periodontal tissue engineering by growth factors. Bone, 19:23S-37S, 1996. Haynesworth, S. E.; Kadiyala, S. & Liang, L. N. Mitogenic stimulation of human mesenchymal stem cells by platelet release suggest a mechanism for enhancement of bone repair by platelet concentrates (2002). Presented at the 48th Meeting of the Orthopedic Research Society, Boston, MA. Hiramatsu, T.; Okamura, T.; Imai, Y; Kurosawa, H.; Aoki, M. & Shinoka, T. Effects of autologous platelet concentrate reinfusion after open heart surgery in patients with congenital heart disease. Ann. Thorac. Surg., 75:1282-5, 2002. Kassolis, J. D.; Rosen, P. S. & Reynolds, M.A. Alveolar ridge and sinus augmentation utilizing platelet rich plasma in combination with freeze-dried bone allograft. Case series. J. Periodontol, 71: 1654-61, 2000. Kevy, S. & Jacobson, M. Preparation of growth factors enriched autologous platelet gel (2001) Proceedings of the 27th Annual Meeting of Service Biomaterials, April. Kim, S. G.; Chung, C. H.; Kim, Y. K; Park, J. C. & Lim, S.C. Use of particulate dentin-plaster of Paris combination with/without platelet rich plasma in the treatment of bone defects around implants. Int. J. Oral. Maxillofac. Implant., 17:86-94, 2002. Lozada, J. L.; Caplanis, N.; Proussaefs, P.; Willardsen, J. & Kammeyer, G. Platelet rich plasma application in sinus graft surgery: Part I, background and processing techniques. J. Oral. Implantol, 27:38-42,2001. Lui, Y; Kalen, A. & Risto, O. Fibroblast proliferation due to exposure to a platelet concentrate in vitro is pH dependent. Wound. Repair. Regen., 10:336, 2002. Man, D.; Plosker, H. & Winland-Brown, J. E. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast. Reconstr. Surg., 107: 229-37, 2001. Marx, R. E.; Carlson, E. R.; Eichstaedt, R. M.; Schimmele, S.R.; Strauss, S. R. & Georgeff, K.R. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod, 85:638-46, 1998. Marx, R. E. Platelet-rich plasma: evidence to support its use. J. Oral. Maxillofac. Surg., 62:489-96, 2004. Mendonca-Caridad, J. J.; Juiz-Lopez, P. & Rubio-Rodriguez, J. P. Frontal sinus obliteration and craniofacial reconstruction with platelet rich plasma in a patient with fibrous dysplasia. Int. J. Oral. Maxillofac. Surg., 55:88-91, 2006. Petrungaro, P. S. Using platelet-rich plasma to accelerate soft tissue maturation in esthetic periodontal surgery. Compend. Contin. Educ. Dent, 22:729-32, 734, 736, 2001. Schliephake, H. Bone growth factors in maxillofacial skeletal reconstruction. Int. J. Oral. Maxillofac. Surg., 31:469-84, 2002. Sitaras, N. M.; Sariban, E.; Pantazis, P.; Zetter, B. & Antoniades, H.N. Human iliac artery endothelial cells express both genes encoding the chains of platelet-derived growth factor (PDGF) and synthesize PDGF-like mitogens. J. Cell. Physiol, 132:316-80, 1987. Weibrich, G.; Kleis, W.K.; Kunz-Kostomanolakis, M.; Loos, A.H. & Wagner, W. Correlation of platelet concentration in platelet-rich plasma to the extraction method, age, sex, and platelet count of the donor. Int. J. Oral. Maxillofac. Implants., 16:693-9, 2001. Weibrich, G.; Gnoth, S.H; Otto, M.; Reichert, T.E.; Wagner, W. Growth stimulation of human osteoblast-like cells by thrombocyte concentrates in vitro. Mund. Kiefer. Geschtschir, 6:168-74,2002. Whitman, D. H; Berry, R. L.; Green, D. M. Platelet gel: An autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J. Oral. Maxillofac. Surg., 55:1294-9, 1997.
Dr. Joao Paulo Mardegan Issa BRAZIL Email: jpmissa@forp.usp.br Received: 21-03-2007 Accepted: 25-05-2007 |